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Multiple displacement amplif ication 
(MDA) is a method of isothermal 
DNA amplification frequently applied 
to whole-genome amplif ication (1). 
MDA typically uti l izes phi29 DNA 
polymerase, which shows exceptional 
processivity along with strong strand-
displacement and exonuclease activity. 
As a consequence, MDA outperforms 
PCR-based approaches in terms 
of template coverage and amplif i-
cation fidelity (2). In addition, strand-
displacement amplification results in 
a hyper-branched product with a high 
molecular weight (≥10 kb), which is 
ideal for library construction in next-
generation sequencing (NGS). For 
these reasons, MDA, in combination 
with NGS, has become a gold standard 
method in genomic research (3–5). A 
long-standing issue in MDA is template-
independent amplification (TIA), partic-
ularly when amplifying ultralow concen-
trations of templates that require high 
concentrations of random hexamer 
primers and an extended incubation 
period (1). Positive amplification due 
to TIA in negative controls not only 
compromises confidence in exper-
imental results, but, more impor-
tantly, generates junk DNA (1). Even 
when using wel l-optimized MDA 
protocols, junk DNA may compose up 
to 70% of the product (1,6,7). Elimi-
nation of junk DNA has attracted 
signif icant investigation, including 
the use of dimethyl sulfoxide (DMSO) 
(8,9), T4 gene 32 (9), trehalose (10), 
single-stranded DNA binding protein 
(SSB) (11), random hexamer primers 
containing an internal C3 spacer (12), 
RNA primer (13), chimeric DNA-RNA 
primer (14), modulation of incubation 
temperature (15), and the reduction of 
reaction volume (16). However, these 
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Multiple displacement amplification (MDA) is widely used in whole-genome/transcriptome amplifi-
cation. However, template-independent amplification (TIA) in MDA is a commonly observed phe-
nomenon, particularly when using high concentrations of random hexamer primers and extended 
incubation times. Here, we demonstrate that the use of random pentamer primers with 5´ ends 
blocked by a C18 spacer results in MDA solely in a template-dependent manner, a technique we 
have named tdMDA. Together with an optimized procedure for the removal of residual genomic 
DNA during RNA extraction, tdMDA was used to profile circulating RNA from 0.2 mL of patient 
sera. In comparison to regular MDA, tdMDA demonstrated a lack of quantifiable DNA amplification 
in the negative control, a remarkable reduction of unmapped reads from Illumina sequencing (7 ± 
10.9% versus 58.6 ± 39%, P = 0.006), and increased mapping rates of the serum transcriptome 
(26.9 ± 7.9% versus 5.8 ± 8.2%, P = 3.8 × 10-4). Transcriptome profiles could be used to separate 
patients with chronic hepatitis C virus (HCV) infection from those with HCV-associated hepatocel-
lular carcinoma (HCC). We conclude that tdMDA should facilitate RNA-based liquid biopsy, as well 
as other genome studies with biological specimens having ultralow amounts of genetic material.
Reports
METHOD SUMMARY
Random pentamer primers blocked at the 5´ end with a C18 spacer were shown to eliminate template-independent 
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options have not been widely adopted. 
Increasing the amount of template (≥10 
ng) and using a short incubation time, as 
recommended in many commercial kits 
such as the REPLI-g kits from QIAGEN, 
is a common option to minimize TIA, yet 
such an amount (10 ng) is not always 
available in many biological scenarios. 
Here, we have developed a robust MDA 
protocol that is free of TIA through the 
use of 5´ end-blocked random pentamer 
primers. Isothermal amplification occurs 
solely in a template-dependent manner, 
which we have named tdMDA. The 
potential of tdMDA has been demon-
strated by an efficient profiling of human 
circulating RNA, a biological source 
notorious for its ultralow concentration 
and complex heterogeneity (17). 
Materials and methods
Patient samples
A total of 30 serum samples were used 
in the current study. Of these, 20 were 
from a completed study (18), and 3 
samples from blood donors were used 
to optimize the experimental protocols 
for RNA extraction, genomic DNA 
removal, and tdMDA. The remaining 
seven samples were collected from 
patients at the Saint Louis University 
Hospital. Three patients had chronic 
HCV infection, and the other four were 
diagnosed with HCV-associated hepato-
cellular carcinoma (HCC) by computed 
tomography (CT), serum a fetoprotein 
(AFP) measurement, and histological 
examination. These samples were used 
to test the feasibility of circulating RNA 
profiling through the use of tdMDA.
Ethics statement
For the collection of serum samples, 
written informed consent was obtained 
from each patient and was approved by 
the local Institutional Review Board in 
the parental studies (19). The research 
protocol for the collection and use of 
patient samples was reviewed and 
approved by the Saint Louis University 
No  Group  Name                    Sequence (5’→ 3’)                                         MDA yield (µg) 
1             2             3             4
Figure 1. List of primers tested in multiple displacement amplification (MDA). Group 1 primers have phosphorothioate bonds placed at different positions 
to test the minimum lengths of primers capable of initiating DNA polymerization. Group 2 primers are modified internally with a C3 spacer to minimize 
self-priming. Group 3 primers are the group 2 primers modified with the inclusion of locked nucleic acid (LNA) to stabilize the binding between primers 
and templates. Groups 4 and 5 are constrained primers and RNA primers (with or without a C3 spacer), respectively. Random primers blocked at the 5´ 
end are designated as group 6 (hexamer) or group 7 (pentamer) primers. In these two groups of primers, the blockage at the 5´ end was tested using dif-
ferent modifications, including inverted, 2´,3´dideoxy-dT base (5´ inverted ddT), dSpacer, C3 spacer, C9 spacer, C18 spacer, amino modifier C6 (AmMC6) 
or alkyne. Degenerate bases are indicated using standard International Union of Pure and Applied Chemistry (IUPAC) codes. Each primer was tested in 
triplicate at a concentration of 50 µM in the standard MDA protocol with (blue) or without (red) template [1 ng of the hepatitis C virus (HCV) plasmid]. 
The MDA reaction with the group 7 primers was incubated at 28°C, while the other groups of primers were amplified at 30°C. The error bars indicate SD.
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Institutional Review Board (IRB protocol: 
SLU15565).
Standard MDA protocol
In order to facilitate experimental optimi-
zation, we defined a standard MDA 
protocol with a reaction volume of 40 µL 
and consisting of phi29 DNA polymerase 
and its corresponding buffer, 1 mM of 
dNTPs, and 2 µM or 50 µM of random 
exonuclease-resistant primers. A recom-
binant 12-kb plasmid (HCV plasmid) 
containing a 9-kb HCV genotype 1a 
genome from our previous study (20) 
was used as a positive control. The 
reaction was incubated at 30°C for 16 
h, followed by heat-inactivation at 65°C 
for 10 min. In addition to visualization 
on a 0.8% agarose gel, MDA yield was 
quantitated by the Quant-iT PicoGreen 
dsDNA Assay kit (QIAGEN, Valencia, CA) 
after purification using the QIAamp DNA 
mini kit. Due to the extreme sensitivity of 
the techniques (5), all MDA experiments 
were performed in strict adherence to 
the recommendations of Champlot et 
al. to avoid possible contamination (21).
Elimination of TIA in MDA
The extreme sensitivity of MDA also 
causes confusion between TIA and 
reagent contamination, wherein the 
latter is caused by trace amounts of 
bacterial or other microbial genomes left 
during manufacture. Without additional 
experimentation, it was difficult to clarify 
if the positive amplification in negative 
controls resulted from TIA or reagent 
contamination. Therefore, a multi-step 
strategy was applied to eliminate TIA 
in MDA. First, using the standard MDA 
protocol, we evaluated the purity of 
phi29 DNA polymerases from various 
vendors, including Lucigen (Middleton, 
WI), Epicentre (Madison, WI), Thermo 
Scientif ic (St. Louis, MO), and New 
England Biolabs (Ipswich, MA). Decon-
tamination through UV irradiation as 
described by Woyke et al. was also 
adopted for the reagents, including 
phi29 DNA polymerase, dNTPs, 
and primers (8). The procedure was 
conducted with the Stratagene Strata-
linker 2400 UV Crosslinker (Agilent 
Technologies, Santa Clara, CA). Next, 
using the standard MDA protocol with 
reagents that were free of contamination, 
elimination of TIA was evaluated by the 
use additives such as DMSO (0.5~5%) 
(Sigma-Aldrich, St. Louis, MO), Esche-
richia coli SSB (50~300 µg/mL) (New 
England Biolabs), and Fc400 (4~64 
mg/mL) (Sigma-Aldrich) to emulate a 
crowded intracellular environment (22). 
The incubation temperature was tested 
from 25°C to 35°C.
Final ly, we focused on pr imer 
optimization by designing a total of 36 
different types of primers that could 
be categorized into 7 groups (Figure 
1). Primers containing locked nucleic 
acid (LNA) were synthesized by Exiqon 
(Woburn, MA). All remaining primers 
were purchased from Integrated DNA 
Technologies (IDT, Coralville, IA). Each 
primer was tested in triplicate at 50 µM, 
a typical concentration used in MDA 
(1,2).
Serum RNA extraction, genomic DNA 
removal, and real-time RT-tdMDA
Total RNA was extracted from 200 µL 
serum using the miRNeasy Serum/
Plasma kit (QIAGEN) and then eluted 
into 14 µL water. Extracted RNA 
was quantitated using the Quant-iT 
RiboGreen RNA kit (Life Technologies, 
R
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St. Louis, MO) on a f luorescence 
microplate reader. Five options were 
tested to remove residual genomic 
DNA during RNA extraction (Supple-
mentary Table S1) using a 12-kb HCV 
plasmid as a spike-in DNA that was 
added to serum prior to RNA extraction 
(1 µg HCV plasmid per 200 µL serum). 
Using purified RNA as the template, a 
30-cycle HCV non-structural gene 3 
(NS3)–specific PCR was conducted 
to determine the efficiency of genomic 
DNA removal.
Purified RNA (9.4 µL) was reverse 
transcr ibed in a 20 µL reaction 
consisting of 1× SuperScript III buffer 
(Life Technologies), 10 mM DTT, 2 
mM dNTPs, 20 U RNasein RNase 
Inhibitor (Promega, Madison, WI), 200 
U SuperScript III reverse transcriptase 
and 80 µM primers. The reaction was 
incubated at 37°C for 30 min, 50°C for 
30 min, and then inactivated at 70°C 
for 15 min. An aliquot of 4 µL of this 
reverse transcription (RT) reaction 
served as the template in the subse-
quent MDA. Both RT and MDA used the 
same random primer capable of elimi-
nating TIA. Using three serum samples 
with different RNA concentrations, we 
conducted real-time RT-tdMDA with 
0.1× SYBR Green I (Thermo Fisher 
Scientific) included in the tdMDA step. 
The reaction was incubated at 28°C 
for 24 h on the ABI 7500 Real-Time 
PCR System (Applied Biosystems, 
Foster City, CA). The resulting curves 
of fluorescent intensity were used to 
determine an optimal incubation time 
for RT-tdMDA applied to HCV and HCC 
patient samples.
Illumina sequencing
The optimized procedures from RNA 
extraction and purification were applied 
to serum samples from seven HCV 
and HCC patients. The cDNA from 
the RT reaction was amplified by both 
tdMDA and the regular MDA protocol 
using random hexamer primers (primer 
6NS2 listed in Figure 1). Based on the 
product size (~20 kb), the purif ied 
RT-MDA product was diluted to 0.4 
ng/µL and enzymatically sheared by 
incubating the DNA at 55°C for 5 min 
using the Nextera XT transposome 
from the Nextera XT DNA Sample 
Preparation kit (Illumina, San Diego, 
CA), which added adapter sequences 
simultaneously. Fragmented DNA was 
amplified with 12 cycles of PCR using 
the Index 1 and Index 2 primers from 
Illumina, followed by purification and 
size selection using AMPure XP beads 
(Beckman Coulter, Beverly, MA). Size-
selected l ibraries were normalized 
using the normalization beads from 
Illumina. In this step, the quantity of 
each library was normalized to ensure 
equal representation in the pooled 
sample. An aliquot of 2 µL normalized 
and pooled library was added to 998 
µL pre-chil led hybridization buf fer, 
denatured at 98°C for 2 min, and then 
sequenced on the Illumina NextSeq 500 
Sequencing platform (1 × 250-bp single 
reads and mid-output) at MOgene (St. 
Louis, MO).
Data analysis
Raw sequence reads in fastq format 
were first filtered in PRINSEQ (v0.19.5) 
for quality control, including read length 
≥70 bp, mean read quality score ≥25, 
low complexity with DUST score ≤7, 
ambiguous bases ≤1%, and all dupli-
cates (18). By subtracting the human 
reference genome, NCBI reference 
sequences for bacteria, viruses and 
fungi, and NCBI nt database (6), we 
calculated and compared the rates of 
unmapped sequencing reads for each 
sample amplified by either tdMDA or 
regular MDA. Potential gene detection 
and differential gene expression (DGE) 
between HCV and HCC patients were 
analyzed by the TopHat-featureCount-
edgeR pipelines (23,24). In brief, filtered 
reads were mapped in TopHat onto the 
annotated human reference genome 
(Ensembl GRCh 38.84). Gene-counting 
data were summarized at the transcript-
level from TopHat output in feature-
Counts (25), followed by DGE analysis 
in edgeR with the false discovery rate 
(FDR) set at 10%.
Statistical analysis
Except for built-in statistical analyses in 
programs such as Cufflinks and edgeR, 
other comparisons were done using 
the two-tailed Student’s t-test. Data 
were expressed as the mean ± SD, and 


















Figure 2. Real-time reverse transcription–template dependent multiple displacement amplifi-
cation (RT-tdMDA) using three hepatitis C virus (HCV) patient serum samples and a negative 
control (H2O). These samples covered the range of the RNA yield extracted from 200 µL serum 
(7.5–19.2 ng), as quantitated in the final 14 mL of elution by the QIAGEN miRNA kit prior to 
HL-DNase digestion. An aliquot of 10.6 mL RNA was used for RT in a reaction containing 200 
U SuperScript III, 80 mM 5´-end-blocked random pentamer primer (5´-/iSpC3/NNN*N*N-3´; 
asterisks denote phosphorothioate bonds), and 2 mM dNTPs in a 20-mL volume. An aliquot 
of 4 mL of the RT reaction was used in a 40-mL tdMDA reaction containing 300 U phi29 DNA 
polymerase (Epicentre), 80 mM primer, and 0.1× SYBR Green I (Thermo Fisher Scientific). 
The reaction was incubated at 28°C for 24 h on the ABI TaqMan 7500, in which fluorescent 
intensities were monitored through the SYBR Green channel. Estimated amount of cDNA input 
in tdMDA = [10.6 / (14 + 0.5 (HL-DNase) + 1.4 (buffer)] × [total RNA amount] × 0.2. Template-
independent amplification was completely inhibited, as indicated by the negative control.
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Data availability
Raw sequence data in fastq format 
from the seven HCV and HCC patient 
samples was deposited in the NCBI 
Sequence Read Archive (SRA) under 
the SRA accession no. SRP071026.
Results and discussion
Reagent contamination and TIA are two 
major concerns in MDA. While these 
issues are negligible when using large 
amounts of template, both concerns 
become significant shortcomings when 
working with low or ultralow amounts 
of template (typically <1 ng) since they 
compress the product space of target 
molecules and/or aggravate quali-
tative biases (2,6,7,26). While reagent 
contamination could be minimized or 
even eliminated through the use of 
clean enzymes and reagents (27,28), 
TIA remains a consistent issue in MDA, 
despite many attempts to overcome it. 
The current study provides a simple, but 
efficient solution in which the use of a 
specially designed primer (C28) (Figure 
1) eliminates TIA.
In a stepwise optimization process, 
we f irst identif ied that phi29 DNA 
polymerase from Epicentre was consid-
erably free of reagent contamination in 
comparison to other enzymes (Supple-
mentary Figure S1). UV treatment of the 
Epicentre phi29 DNA polymerase elimi-
nated contamination, but MDA yield was 
reduced, while UV treatment of dNTPs 
or random hexamer primers abolished 
or compromised the reaction (Supple-
mentary Figure S2). In the standard MDA 
protocol using the phi29 enzyme from 
Epicentre, all additives had no apparent 
role in eliminating TIA (Supplementary 
Figure S2). Incubation temperatures 
>31°C reduced yield, while tempera-
tures <30°C enhanced TIA (Supple-
mentary Figure S2). These results led us 
to focus on primer design to eliminate 
TIA in MDA.
 As expected from the strong 3´→5´ 
exonuclease activity of phi29 DNA 
polymerase, which digests oligonucle-
otides (29), Primer 6N of the Group 1 
primers produced no DNA amplification. 
Primers C5 and C6 failed to amplify the 
HCV plasmid, while the performance of 
Primer C7 was similar to the random 
hexamer primer (Primer 6NS2) (Figure 
1). Internal modification of the C3 spacer 
caused steric hindrance. However, such 
hindrance, as shown with the Group 2 
primers, cannot differentiate between 
self and primer-template priming, which 
was not improved by the inclusion of 
LNA bases (Group 3). Despite the 
theoretical possibility (30), RNA primers 
(Group 4) were incapable of inhibiting 
TIA. The constrained primers in Group 5 
resulted in an overall reduction of MDA 
yields, and TIA was still observed.
Substantial suppression of TIA was 
found in MDA using 5´ end-blocked 
random hexamer (Group 6) or pentamer 
(Group 7) primers (Figure 1). Of the 
eight options to block 5´ ends of 
random pentamer primers, consecutive 
dSpacer (1´,2´-dideoxyribose) (Primer 
C22), amino modifier C6 (Primer C30) 
and hexynyl (Primer C31) produced no 
amplification at all. While other options 
showed a substantial suppression 
of TIA, consistent suppression of 
TIA resulting in increased reproduc-
ibility was only achieved using the 
C18 spacer modification (Primer C28), 
suggesting the subtle influence of the 
dif ferent blocking options (Figure 1). 
Given the decreased melting temper-
atures of random pentamer primers 
in comparison to random hexamer 
primers, the incubation temperature 
in MDA with the Group 7 primers was 
initially reduced from 30°C to 28°C. In 
subsequent experiments with Primer 
C28, this temperature appeared to be 
optimal with regard to the complete 
elimination of TIA and provided MDA 
yields comparable to the use of the 
random hexamer pr imers with or 
without C18 spacer–blocked 5´ ends 
(Figure S3).
The tdMDA reaction could tolerate 
primer concentrations up to 400 µM 
(Supplementary Figure S4). Beyond this 
threshold, yield was reduced dramati-
cally, perhaps due to decreased Mg2+ 
concentration caused by binding to 
primer (31). For HCV plasmid amounts 
ranging from 1 ng to 50 pg, tdMDA yields 
were maximized with primer concen-
trations of 80–100 µM. When the input 
amount was lower than 50 pg in a 40-µL 





Figure 3. Transcriptome sequencing of circulating RNA. (A) RNA extracted from seven pa-
tient serum samples was amplified using real-time reverse transcription–template dependent 
multiple displacement amplification (RT-tdMDA). Lanes 1–2: negative control (water); Lanes 
3–9: seven hepatitis C virus (HCV) and hepatocellular carcinoma (HCC) patient serum sam-
ples; M: lambda DNA/HindIII marker. (B) Comparisons of the percentages of unmapped reads 
and TopHat mapping rates between tdMDA and regular MDA. (C) Differential gene expression 
(DGE) analysis in edgeR identified 457 genes showing ≥2 fold changes either up- (n = 424) 
or down-regulation (n = 23) in the HCC group. (D) Unsupervised clustering analysis among 
HCV and HCC patients based on the leading log-fold-change of detected gene transcripts.
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be freshly prepared. After being resus-
pended in water, Primer C28 with the 
C18 spacer modification was consid-
erably stable. No apparent reduction in 
MDA yields was seen when using Primer 
C28 subjected to 30 thaw-freeze cycles 
(Supplementary Figure S5). Similarly, 
tdMDA was reproducible when using 
Primer C28 stored up to 6 months at 
-20°C (Supplementary Figure S5).
The mechanisms for TIA gener-
ation in MDA are not fully understood. 
However, based on the observations 
from the current study, we speculate 
there two possibilities: (i ) polymerase 
jumping and (ii ) self-priming. It has long 
been known that Taq DNA polymerase 
is capable of jumping among templates 
(32). We believe that this kind of activity 
might be enhanced by phi29 DNA 
polymerase due to the polymerase’s 
inability to be used as a molecular brake 
in comparison to Taq DNA polymerase 
(Sahu, S. PhD thesis, Duke University, 
2007). Polymerase jumping among 
random primers could form artificial 
templates for the generation of TIA. This 
process was abolished by blocking the 
5´ ends of random primers. On the other 
hand, self-priming is thought to be a 
common mechanism responsible for 
artifacts in PCR and MDA (12). Our data 
showed no product was generated in 
MDA with Primer C5, which was actually 
4-bp in length after digestion owing to 
the exonuclease activity of phi29 DNA 
polymerase. Thus, efficient polymer-
ization by phi29 DNA polymerase may 
require 5-bp priming, which would 
potentially allow self-priming among 
random hexamer (6 bp) primers. This 
may explain why TIA cannot be elimi-
nated entirely through the use of random 
hexamer primers with 5´ ends blocked 
by the C18 spacer (Figure 1). Primers 
C1 and C2 have an internal modifi-
cation of the C3 spacer that theoreti-
cally prevents self-priming. Primer C25 
is a random pentamer primer without 
modification. The use of these primers 
produces a significant amount of TIA 
(Figure 1). Based on these observations, 
polymerase jumping, rather than self-
priming, might be the critical factor for 
TIA formation in MDA.
 Finally, tdMDA was evaluated for 
profiling circulating RNA. The average 
RNA recovery from 200 µL serum 
was 10.76 ± 2.8 ng using the QIAGEN 
miRNeasy Serum/Plasma kit. After 
optimizing genomic DNA removal 
(Supplementary Table S1), 3 serum 
samples with various RNA yields were 
selected for real-time RT-MDA with a 
24-h incubation. While DNA accumu-
lation was not observed in the negative 
control (water), amplification of all 3 
samples with 10-fold serial dilutions 
plateaued after an approximately 18-h 
incubation (Figure 2). The protocol 
was then applied to the seven HCV 
and HCC patient samples (Figure 
3A). Illumina sequencing of RT-tdMDA 
product provided an average of 1.45 
million reads per sample. Unmapped 
reads were significantly lower in tdMDA 
than regular MDA with random hexamer 
primers (7 ± 10.9% versus 58.6 ± 39%; P 
= 0.006) (Figure 3B). Data generated via 
tdMDA showed a much higher mapping 
rate than regular MDA in TopHat (26.9 ± 
7.9% versus 5.8 ± 8.2%; P = 3.8 × 10-4) 
(Figure 3B). The TopHat-feature Counts-
edgeR analysis detected 3459 genes in 
human circulating RNA. Of these 3459 
genes, 457 showed ≥2 fold changes, 
either up- (n = 424) or down-regulated 
(n = 23) in the HCC group (Figure 
2C). Notably, unsupervised clustering 
analysis showed a clear separation of 
HCV from HCC based on the leading 
log-fold-change, which is the root-
mean-square average of the largest 
log2-fold-changes between each pair 
of samples (Figure 2D) (24). 
Here, we reported a simple but 
reliable solution for the elimination of 
TIA in MDA. Template-dependent ampli-
fication should extend MDA’s appli-
cation to biological specimens with low 
or ultralow amounts of genetic material. 
By applying tdMDA, we demonstrated 
that efficient profiling of circulating RNA 
can be achieved from as little as 0.2 mL 
patient serum. Substantial differences 
in transcriptome profiles between HCV 
and HCC patients further demonstrate 
the promise of tdMDA for RNA-based 
liquid biopsy applications.
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